País: Canadà
Idioma: anglès
Font: Health Canada
ACETYLSALICYLIC ACID
LABORATOIRES TRIANON INC.
B01AC06
ACETYLSALICYLIC ACID
81MG
TABLET (DELAYED-RELEASE)
ACETYLSALICYLIC ACID 81MG
ORAL
120/150/300
OTC
SALICYLATES
Active ingredient group (AIG) number: 0101169013; AHFS:
APPROVED
2015-12-11
_ASA 81 MG - Product Monograph _ _ _ _Page 1 of 44 _ PRODUCT MONOGRAPH ASA 81 MG Acetylsalicylic Acid Delayed Release Tablets 81 mg USP Platelet aggregation inhibitor LABORATOIRES TRIANON INC. 660 Boul. Industriel Blainville, Quebec J7C 3V4 www.labriva.com Date of Preparation: December 11, 2015 Date of Revision: September 28, 2022 Control Number: 267165 _ASA 81 MG - Product Monograph _ _ _ _Page 2 of 44 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ............................................................................................ 4 WARNINGS AND PRECAUTIONS ............................................................................ 4 ADVERSE REACTIONS............................................................................................. 6 DRUG INTERACTIONS ............................................................................................. 7 DOSAGE AND ADMINISTRATION .......................................................................... 9 OVERDOSAGE .........................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY.........................................................11 STORAGE AND STABILITY ....................................................................................12 DOSAGE FORMS, COMPOSITION AND PACKAGING ..........................................12 PART II: SCIENTIFIC INFORMATION .......................................................................... 13 PHARMACEUTICAL INFORMATION .....................................................................13 CLINICAL TRIALS ...................................................................................................14 DETAILED PHARMACOLOGY....................... Llegiu el document complet